Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5288351
Max Phase: Preclinical
Molecular Formula: C36H60N10O17S2
Molecular Weight: 969.06
Associated Items:
ID: ALA5288351
Max Phase: Preclinical
Molecular Formula: C36H60N10O17S2
Molecular Weight: 969.06
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CS)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O
Standard InChI: InChI=1S/C36H60N10O17S2/c1-15(2)9-21(33(59)39-16(3)28(54)38-10-25(49)41-24(14-65)36(62)63)44-35(61)23(12-48)46-32(58)20(6-8-27(52)53)43-34(60)22(11-47)45-29(55)17(4)40-31(57)19(5-7-26(50)51)42-30(56)18(37)13-64/h15-24,47-48,64-65H,5-14,37H2,1-4H3,(H,38,54)(H,39,59)(H,40,57)(H,41,49)(H,42,56)(H,43,60)(H,44,61)(H,45,55)(H,46,58)(H,50,51)(H,52,53)(H,62,63)/t16-,17-,18-,19-,20-,21-,22-,23-,24-/m0/s1
Standard InChI Key: BVQRFQYOZQQBQL-WIKDVRPQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 969.06 | Molecular Weight (Monoisotopic): 968.3579 | AlogP: -6.95 | #Rotatable Bonds: 31 |
Polar Surface Area: 440.28 | Molecular Species: ACID | HBA: 17 | HBD: 17 |
#RO5 Violations: 3 | HBA (Lipinski): 27 | HBD (Lipinski): 16 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.42 | CX Basic pKa: 7.79 | CX LogP: -10.01 | CX LogD: -16.28 |
Aromatic Rings: 0 | Heavy Atoms: 65 | QED Weighted: 0.03 | Np Likeness Score: 0.12 |
1. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S.. (2022) Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition., 65 (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177] |
Source(1):